|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2021-08-13 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2018-08-30 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2017-12-19 |
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy
Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy
Trial Type : Single arm, prospective trial
Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib)
Treatment Groups : Single arm
Number of trial participants : 30
Non-randomized clinical trial to compare the immunogenicity of revaccination with 23-valent pneumococcal polysaccharide vaccine between healthy elderly and those with diabetes in Korea
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, to Evaluate the Effect of Ertugliflozin on Cardiac Function in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control and Stage B Heart Failure
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic medications including DPP4 inhibitors.
100 项与 MSD Korea Co. Ltd. 相关的临床结果
0 项与 MSD Korea Co. Ltd. 相关的专利(医药)
100 项与 MSD Korea Co. Ltd. 相关的药物交易
100 项与 MSD Korea Co. Ltd. 相关的转化医学